

September 15, 2016

Re: LB390 Annual Report

Dear Chairs of Judiciary and Health & Human Services Committees,

On the behalf of the University of Nebraska Medical Center and Deepak Madhavan, MD, we respectfully submit the annual report for the Cannabidiol Pilot Study. This study allows access to cannabidiol oil for patients who suffer from intractable or treatment-resistant seizures. The catalyst for the study was LB390 introduced by Senator Sue Crawford.

The study has generated significant interest and response from patients and providers throughout the State of Nebraska. To date, a total of 64 medical records of potential study participants have been reviewed. Furthermore, we are still accepting medical records for review.

Currently, 5 individuals have been consented for potential participation in the Cannabidiol Study. Each of these patients are in the preliminary screening period and no one has initiated cannabidiol as of this time. Following the screening period, the individuals will be offered the opportunity to be enrolled in the study if they meet the inclusion and exclusion criteria. After enrollment, data will be collected and documented regarding changes in intractable seizure frequency and severity, adverse effects of treatment, along with a summary of dosing.

Although we are only in the early stages of study protocol implementation, due in large part to regulatory processes of the DEA and FDA with regard to cannabidiol research, we are now moving forward in screening and enrolling eligible patients. We greatly appreciate the support provided for this study on behalf of those Nebraska residents living with this chronic and debilitating condition.

Sincerely,



Christopher J. Kratochvil, M.D.
Associate Vice Chancellor for Clinical Research, UNMC
Vice President for Research, Nebraska Medicine